Business
Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting
SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology programs: IL-2 agonist, bempegaldesleukin (BEMPEG), and IL-15 agonist, NKTR-255. The company will be presenting clinical data for BEMPEG from the ongoing PROPEL study in patients with non-small cell lung cancer (NSCLC) at the 2021 European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress in Geneva, Switzerland from December 8 to December 11, 2021. In addition, two clinical data presentations for NKTR-255 in patients with relapsed/refractory hematologic malignancies will be presented during the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia from December 11 to December 14, 2021.\n\n \n \n \n \n \n \n\n \nPresentation at 2021 ESMO-IO:\nAbstract #140P: \"Preliminary results from PROPEL: A phase 1/2 study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC,\" Felip, E., et al.\nePoster will be on display on the ESMO-IO 2021 virtual meeting platform on Monday, December 6, 2021, at 12:00 pm GMT (7:00 a.m. ET)Presentations at ASH\nAbstract #3134: \"Safety, Tolerability, PK/PD, and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies,\" Shah, N., et al.\nPresenter: Nina Shah, M.D. Session 203: Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III ePoster will be on display on the ASH 2021 virtual meeting platform on Monday, December 13, 2021, at 6:00 a.m. ETAbstract #2815: \"Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T cells: Preliminary results from a Phase 1 Study,\" Turtle, C., et al.\nPresenter: Alexandre Hirayama, M.D. Session 704: Cellular Immunotherapies: Clinical: Poster II ePoster will be on display on the ASH 2021 virtual meeting platform on Sunday, December 12, 2021, at 6:00 a.m. ETCompany to Host Webcast Analyst and Investor Conference Call During ESMO-IO Congress 2021\nThe company will host a conference call and webcast for analysts and investors on Monday, December 6, 2021, at 1:00 p.m. GMT (8:00 ...